Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Inovio Biomedical's Selective Electrochemical Tumor Ablation Therapy Shows Safety, Tolerability, and Significant Complete Responses in Breast Cancer Study
July 4th, 2007
Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced that interim results from an FDA-approved Phase I/II study of 10 patients with recurrent breast cancer treated with Inovio's Selective Electrochemical Tumor Ablation (SECTA) therapy showed the therapy was safe, well-tolerated, and achieved a 75% complete tumor response rate. The study results are being presented in a poster presentation titled, "A Safety and Efficacy Study of Bleomycin Sulfate and Electroporation in Patients with Metastatic or Locally Recurrent Breast Cancer,"...
Source: Vaccine Weekly (2007-07-04)
|
